Company: RVRC
Filing Date: 2025-10-03
Form Type: S-1/A
Source: 0001213900-25-096094
Chunk: 97

Company: Revium Rx.
Filing Date: 2025-10-03
Form: S-1/A
Chunk 97
---
 higher per-course costs. Market penetration 
 percentages are illustrative, epidemiology varies by region, and treatment policies differ substantially across geographies            |     |                                                           |

Explanatory note: For invasive MRSA we apply a conservative 3× U.S. for global multiplier, versus 4× for ceftriaxone-resistant gonorrhea, due to the following:

| ● | Care                                                                                         
 setting: MRSA treatment is hospital-based and tightly controlled by stewardship/formulary    
 policies, slowing adoption abroad. Gonorrhea is outpatient, single-dose, and rapidly updated 
 in global protocols.                                                                         |

<div align='center'>61</div>

| ● | Competition                                                                                    
 & use patterns: MRSA faces entrenched, low-cost generics (vancomycin, linezolid, daptomycin),  
 with new drugs often reserved for salvage cases. Gonorrhea has few alternatives, so resistance 
 drives faster substitution and greater demand not just in the U.S., but globally.              |

| ● | Pricing                                                                                 
 & procurement: anti-MRSA agents face steep ex-U.S. discounts, limiting revenue scaling. 
 Gonorrhea pricing is lower but scales more directly with higher patient volumes.        |

To conclude:

| ● | MRSA                                                                               
 (3×): reflects slower uptake, stronger generic competition, and price compression. |

| ● | Gonorrhea                                                                                
 (4×): reflects higher ex-U.S. burden, faster uptake, fewer alternatives, and more direct 
 revenue translation.                                                                     |

The assumed pricing profile is based on benchmarks
from systemic antibiotics used for resistant infections. While the potential application of Nano-Mupirocin in high-mortality, high-cost
indications such as invasive MRSA supports commercial attractiveness and meaningful global revenue potential, these estimates are our
assumptions that are illustrative only. Actual outcomes will depend on future clinical trial results, regulatory approvals, regional
treatment guidelines, reimbursement decisions, and market adoption.

Our product candidate is still in preclinical
development and has not been approved by any regulatory authority. We do not yet know the final dosage, or number of injections required
per treatment course, and actual pricing will depend on multiple factors including clinical results, regulatory approval, reimbursement,
adoption, and competition.

References

| 1. | https://www.tropicalmedicine.ox.ac.uk/gram/news/drug-resistant-enteric-fever-has-risen-53-percent-since-1990-gram-study-estimates |

| 2